JP2016504384A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504384A5 JP2016504384A5 JP2015551792A JP2015551792A JP2016504384A5 JP 2016504384 A5 JP2016504384 A5 JP 2016504384A5 JP 2015551792 A JP2015551792 A JP 2015551792A JP 2015551792 A JP2015551792 A JP 2015551792A JP 2016504384 A5 JP2016504384 A5 JP 2016504384A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- biguanide compound
- eudragit
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 58
- 229940123208 Biguanide Drugs 0.000 claims description 28
- -1 biguanide compound Chemical class 0.000 claims description 24
- 239000002702 enteric coating Substances 0.000 claims description 17
- 238000009505 enteric coating Methods 0.000 claims description 17
- 239000006186 oral dosage form Substances 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 229920003136 Eudragit® L polymer Polymers 0.000 claims description 8
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 8
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 8
- 201000001421 hyperglycemia Diseases 0.000 claims description 6
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims description 5
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 230000001771 impaired effect Effects 0.000 claims description 4
- 229960003105 metformin Drugs 0.000 claims description 4
- 230000008085 renal dysfunction Effects 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- 206010028813 Nausea Diseases 0.000 claims description 2
- 208000001280 Prediabetic State Diseases 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 229960004111 buformin Drugs 0.000 claims description 2
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000006549 dyspepsia Diseases 0.000 claims description 2
- 208000028208 end stage renal disease Diseases 0.000 claims description 2
- 201000000523 end stage renal failure Diseases 0.000 claims description 2
- 230000037406 food intake Effects 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
- 239000001087 glyceryl triacetate Substances 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 208000006443 lactic acidosis Diseases 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 229960004329 metformin hydrochloride Drugs 0.000 claims description 2
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 230000008693 nausea Effects 0.000 claims description 2
- 229960003243 phenformin Drugs 0.000 claims description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 229940033134 talc Drugs 0.000 claims description 2
- 235000012222 talc Nutrition 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 229960005196 titanium dioxide Drugs 0.000 claims description 2
- 229960002622 triacetin Drugs 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 230000008673 vomiting Effects 0.000 claims description 2
- 230000004584 weight gain Effects 0.000 claims description 2
- 235000019786 weight gain Nutrition 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 230000002411 adverse Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 239000003446 ligand Substances 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 238000009472 formulation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960004034 sitagliptin Drugs 0.000 description 3
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 3
- 230000000723 chemosensory effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108091005708 gustatory receptors Proteins 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- MIEKOFWWHVOKQX-UHFFFAOYSA-N (S)-2-(4-Methoxyphenoxy)propanoic acid Chemical compound COC1=CC=C(OC(C)C(O)=O)C=C1 MIEKOFWWHVOKQX-UHFFFAOYSA-N 0.000 description 1
- 102000017002 Bile acid receptors Human genes 0.000 description 1
- 108070000005 Bile acid receptors Proteins 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960002397 linagliptin Drugs 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000019583 umami taste Nutrition 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361749307P | 2013-01-05 | 2013-01-05 | |
| US61/749,307 | 2013-01-05 | ||
| PCT/US2014/010240 WO2014107617A1 (en) | 2013-01-05 | 2014-01-03 | Delayed-release composition comprising biguanide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016504384A JP2016504384A (ja) | 2016-02-12 |
| JP2016504384A5 true JP2016504384A5 (enExample) | 2017-02-09 |
| JP6333855B2 JP6333855B2 (ja) | 2018-05-30 |
Family
ID=50030486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551792A Active JP6333855B2 (ja) | 2013-01-05 | 2014-01-03 | ビグアナイドを含む遅延放出組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20140193498A1 (enExample) |
| EP (2) | EP2941245B1 (enExample) |
| JP (1) | JP6333855B2 (enExample) |
| KR (1) | KR102229492B1 (enExample) |
| CN (2) | CN110051638B (enExample) |
| AR (1) | AR094374A1 (enExample) |
| AU (1) | AU2014203942B2 (enExample) |
| CA (1) | CA2896864C (enExample) |
| CL (1) | CL2015001914A1 (enExample) |
| CU (1) | CU20150071A7 (enExample) |
| EA (1) | EA039530B1 (enExample) |
| HK (1) | HK1214966A1 (enExample) |
| IL (1) | IL239722B (enExample) |
| MX (2) | MX376822B (enExample) |
| NZ (1) | NZ709525A (enExample) |
| PH (1) | PH12015501520A1 (enExample) |
| SG (2) | SG11201505240QA (enExample) |
| WO (1) | WO2014107617A1 (enExample) |
| ZA (1) | ZA201504858B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| SG191855A1 (en) | 2011-01-07 | 2013-08-30 | Elcelyx Therapeutics Inc | Chemosensory receptor ligand-based therapies |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| NZ626578A (en) | 2012-01-06 | 2016-11-25 | Elcelyx Therapeutics Inc | Compositions and methods for treating metabolic disorders |
| ES2832773T3 (es) | 2012-01-06 | 2021-06-11 | Anji Pharma Us Llc | Composiciones de biguanida y métodos de tratamiento de trastornos metabólicos |
| SI3236943T1 (sl) * | 2014-12-24 | 2023-06-30 | Principia Biopharma Inc. | Sestavki za dostavo zdravila v ileum-jejunum |
| US10744070B2 (en) | 2015-06-19 | 2020-08-18 | University Of Southern California | Enteral fast access tract platform system |
| US10631564B2 (en) | 2015-06-19 | 2020-04-28 | University Of Southern California | Enterically coated microparticle compositions and methods for modified nutrient delivery |
| US20190382462A1 (en) * | 2017-01-13 | 2019-12-19 | Pietro P. Sanna | Methods and compositions for treating hpa hyperactivity |
| FR3068601B1 (fr) * | 2017-07-05 | 2021-02-19 | Eric Joseph Marie Fulgence Janin | Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire |
| KR20220024189A (ko) * | 2019-06-03 | 2022-03-03 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 지연 방출 소프트젤 캡슐 |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| US20230000820A1 (en) * | 2021-06-28 | 2023-01-05 | ImmunoMet Therapeutics, Inc. | Solid dosage form of n-1-pyrrolidine-n-5-(3-trifluoromethoxy)phenyl biguanide and uses thereof |
| CN119499203A (zh) | 2023-08-22 | 2025-02-25 | 雅研(天津)生物医药科技中心(有限合伙) | 一种盐酸二甲双胍肠溶片 |
| CN119499228A (zh) | 2023-08-22 | 2025-02-25 | 雅研(天津)生物医药科技中心(有限合伙) | 盐酸二甲双胍肠溶制剂 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1209253A (en) | 1913-01-09 | 1916-12-19 | Automatic Electric Co | Impulse-transmitting device. |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| JPS58403B2 (ja) | 1975-07-24 | 1983-01-06 | 武田薬品工業株式会社 | Ｌ− アスコルビンサンセイザイノ セイゾウホウ |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5135757A (en) | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| FR2704146B1 (fr) | 1993-04-19 | 1995-07-13 | Cripdom | Microcapsules d'acide acétylsalicylique à libération contrôlée. |
| US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
| KR100891756B1 (ko) | 1997-04-15 | 2009-04-07 | 씨에스아이알 | 식욕 억제 활성을 갖는 약학 조성물 |
| US5891919A (en) | 1997-09-19 | 1999-04-06 | Burlington Bio-Medical & Scientific Corp. | Denatonium capsaicinate and methods of producing the same |
| US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| ITMI991316A1 (it) | 1999-06-14 | 2000-12-14 | Cip Ninety Two 92 S A | Composizioni farmaceutiche orali a rilascio modificato di mesalazina |
| IL132313A0 (en) | 1999-10-11 | 2001-03-19 | Yeda Res & Dev | Leptin assay |
| US20110217394A1 (en) | 2000-12-05 | 2011-09-08 | Brett Justin West | Iridoid Based Formulations |
| US7964216B2 (en) * | 2001-01-12 | 2011-06-21 | Sun Pharma Advanced Research Company Limited | Spaced drug delivery system |
| WO2002078617A2 (en) | 2001-03-28 | 2002-10-10 | University Of South Florida | Materials and methods for treatment of cancer and identification of anti-cancer compounds |
| US8030008B2 (en) | 2001-04-05 | 2011-10-04 | Senomyx, Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
| FR2830447B1 (fr) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
| US6830759B2 (en) * | 2002-06-28 | 2004-12-14 | Ajinomoto Co., Inc. | Antidiabetic preparation for oral administration |
| US20060019346A1 (en) | 2002-07-29 | 2006-01-26 | Senomyx, Inc. | Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands |
| AU2003261298A1 (en) * | 2002-08-02 | 2004-02-23 | Penwest Pharmaceuticals Company | Sustained release formulations of metformin |
| CN1413582A (zh) * | 2002-11-29 | 2003-04-30 | 贵州圣济堂制药有限公司 | 盐酸二甲双胍肠溶片及其制备方法 |
| DE60320682T2 (de) | 2002-12-18 | 2009-06-10 | Givaudan S.A. | Chimäre alpha q-gustducin g-proteine |
| DE10308504A1 (de) | 2003-02-26 | 2004-09-09 | Basf Ag | Enzymatische Herstellung von (Meth)acrylsäureestern |
| WO2005009351A2 (en) | 2003-07-17 | 2005-02-03 | Santé International, Inc. | Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabetics |
| US8158372B2 (en) | 2004-04-20 | 2012-04-17 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Agonists of a bitter taste receptor and uses thereof |
| US20060024335A1 (en) | 2004-07-29 | 2006-02-02 | Roger Stier E | Oral compositions which mask the bitter taste of a bitter-tasting agent |
| WO2006053771A2 (en) | 2004-11-18 | 2006-05-26 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Stiftung Des Öffentlichen Rechts | Agonists of bitter taste receptors and uses thereof |
| US20060222709A1 (en) * | 2005-03-18 | 2006-10-05 | Agi Therapeutics Research Ltd. | Metformin methods and formulations for treating chronic constipation |
| EP1878734A4 (en) | 2005-04-28 | 2010-02-17 | Ajinomoto Kk | NEW COMPOUND LACTAME |
| US20060269617A1 (en) | 2005-05-26 | 2006-11-30 | Suracell, Inc. | Supplement compositions and method of use for enhancement of insulin sensitivity |
| JP2009501317A (ja) | 2005-06-22 | 2009-01-15 | セノミクス・インコーポレーテッド | コーヒー中の苦味分子（クロロゲン酸ラクトン）により活性化されるヒトｔ２ｒ受容体の同定、およびヒト苦味味覚モジュレーターを同定するための関連するアッセイ |
| CA2620370A1 (en) * | 2005-08-30 | 2007-03-22 | Nicholas Piramal India Limited | Extended release pharmaceutical composition of metformin and a process for producing it |
| FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| US20070104805A1 (en) | 2005-11-01 | 2007-05-10 | Udell Ronald G | Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives |
| JP2007215162A (ja) | 2006-01-11 | 2007-08-23 | Canon Inc | 情報処理装置及びその制御方法、プログラム、記憶媒体 |
| US20070207227A1 (en) | 2006-02-23 | 2007-09-06 | Conopco, Inc., D/B/A Unilever, A Corporation Of New York | Appetite suppressant compositions |
| WO2007116404A2 (en) | 2006-04-10 | 2007-10-18 | Bar-Ilan University | Cucurbitacin glucosides and use thereof in treating cancer |
| CA2551706A1 (en) | 2006-06-27 | 2007-12-27 | Innovative Life Sciences Corporation | Herbal product comprising cinnamon and bitter melon |
| CN100596277C (zh) | 2006-07-10 | 2010-03-31 | 博仲盛景医药技术（北京）有限公司 | 一种促进肠胃蠕动的药物组合物 |
| AP2518A (en) | 2006-08-17 | 2012-11-28 | Unilever Plc | Processes for production of hoodia plant extracts containing steroidal glycosides |
| CN101505772A (zh) | 2006-08-24 | 2009-08-12 | 荷兰联合利华有限公司 | 制备包含甾体糖苷的组合物的方法 |
| WO2008030429A2 (en) | 2006-09-05 | 2008-03-13 | Senomyx, Inc. | Novel haplotype of human t2r receptor ht2r50 and its use in assays for identifying human bitter taste modulators |
| EP1975612A1 (en) | 2007-03-29 | 2008-10-01 | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand | Agonists of bitter taste receptors and uses thereof |
| EP1975611A1 (en) | 2007-03-29 | 2008-10-01 | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand | Agonists of bitter taste receptors and uses thereof |
| US20090042813A1 (en) | 2007-08-10 | 2009-02-12 | Sergey Michailovich Melnikov | Hoodia extract oil compositions comprising medium chain triglycerides |
| WO2009053980A2 (en) | 2007-10-24 | 2009-04-30 | Arava Hoodia Growers A. C. S. Ltd. | An improved appetite suppressant |
| EP2236149B1 (en) | 2008-01-29 | 2014-06-18 | Nakamori Pharmaceutical Co., Ltd. | Medicinal composition for treating respiratory infectious diseases |
| WO2009140784A1 (en) | 2008-05-23 | 2009-11-26 | Givaudan Sa | Bitter alkaloid containing consumables comprising bitter blockers |
| WO2009149577A1 (en) | 2008-06-13 | 2009-12-17 | Givaudan Sa | Methods of identifying modulators of the bitter taste receptor tas2r44 |
| EP2329271B1 (en) | 2008-08-29 | 2012-06-20 | Givaudan SA | Methods to identify modulators |
| WO2010024393A1 (ja) | 2008-08-29 | 2010-03-04 | サントリーホールディングス株式会社 | 新規エピガロカテキンガレート４量体、およびそれらを含む血管内皮機能改善剤 |
| WO2010060198A1 (en) | 2008-11-26 | 2010-06-03 | West Central Envirotech Inc. | Composition and method for controlling insects |
| EP2385049A4 (en) | 2009-01-03 | 2012-08-08 | Shizuoka Prefecture Public University Corp | SULFATED C-GLYCOSIDE, METHOD FOR THE ISOLATION THEREOF AND METHOD FOR THE SYNTHESIS THEREOF |
| US8709745B2 (en) | 2009-07-28 | 2014-04-29 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Methods for isolating ligands of the human bitter taste receptor TAS2R49 |
| EP2490695B1 (en) | 2009-10-21 | 2013-11-20 | Wisconsin Alumni Research Foundation | Method of preventing type 1 diabetes |
| US20120237456A1 (en) | 2009-12-04 | 2012-09-20 | Colgate-Palmolive Company | Oral compositions containing extracts of garcinia mangostana l. and related methods |
| EP2345646A1 (en) | 2010-01-14 | 2011-07-20 | InterMed Discovery GmbH | Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions |
| US20110293753A1 (en) | 2010-05-28 | 2011-12-01 | Louis Bellafiore | Tocotrienol Compositions |
| GB201009873D0 (en) | 2010-06-14 | 2010-07-21 | Univ Leuven Kath | Method for hydrogenation of isoalpha-acids (isohumulones) to hexahydro-iso-alpha-acids (hexahydro-isohumulones) by using heterogeneous ruthenium |
| EP2397039A1 (en) | 2010-06-21 | 2011-12-21 | Abbott Laboratories | Compositions for delaying progression of diabetes using Salacia oblonga extract |
| CN101978956B (zh) * | 2010-10-13 | 2012-03-28 | 北京京丰制药有限公司 | 盐酸二甲双胍肠溶片及其制备方法 |
| SG191855A1 (en) * | 2011-01-07 | 2013-08-30 | Elcelyx Therapeutics Inc | Chemosensory receptor ligand-based therapies |
| NZ626578A (en) * | 2012-01-06 | 2016-11-25 | Elcelyx Therapeutics Inc | Compositions and methods for treating metabolic disorders |
| CN103768071B (zh) * | 2012-10-23 | 2016-08-17 | 中国医药工业研究总院 | 一种治疗糖尿病的口服制剂 |
-
2014
- 2014-01-03 EP EP14702108.3A patent/EP2941245B1/en active Active
- 2014-01-03 KR KR1020157019855A patent/KR102229492B1/ko active Active
- 2014-01-03 MX MX2015008625A patent/MX376822B/es active IP Right Grant
- 2014-01-03 EA EA201591085A patent/EA039530B1/ru unknown
- 2014-01-03 CN CN201910033955.XA patent/CN110051638B/zh active Active
- 2014-01-03 JP JP2015551792A patent/JP6333855B2/ja active Active
- 2014-01-03 HK HK16103014.8A patent/HK1214966A1/zh unknown
- 2014-01-03 NZ NZ709525A patent/NZ709525A/en unknown
- 2014-01-03 CN CN201480003932.XA patent/CN105101956B/zh active Active
- 2014-01-03 US US14/147,449 patent/US20140193498A1/en not_active Abandoned
- 2014-01-03 AU AU2014203942A patent/AU2014203942B2/en active Active
- 2014-01-03 SG SG11201505240QA patent/SG11201505240QA/en unknown
- 2014-01-03 CA CA2896864A patent/CA2896864C/en active Active
- 2014-01-03 EP EP24184490.1A patent/EP4410380A3/en active Pending
- 2014-01-03 MX MX2020011594A patent/MX389344B/es unknown
- 2014-01-03 WO PCT/US2014/010240 patent/WO2014107617A1/en not_active Ceased
- 2014-01-03 SG SG10201705437SA patent/SG10201705437SA/en unknown
- 2014-01-06 AR ARP140100044A patent/AR094374A1/es not_active Application Discontinuation
-
2015
- 2015-06-30 IL IL239722A patent/IL239722B/en unknown
- 2015-07-03 CL CL2015001914A patent/CL2015001914A1/es unknown
- 2015-07-03 PH PH12015501520A patent/PH12015501520A1/en unknown
- 2015-07-06 CU CUP2015000071A patent/CU20150071A7/es unknown
- 2015-07-06 ZA ZA2015/04858A patent/ZA201504858B/en unknown
-
2019
- 2019-11-26 US US16/695,498 patent/US20200093750A1/en not_active Abandoned
-
2024
- 2024-05-20 US US18/668,709 patent/US20250000804A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016504384A5 (enExample) | ||
| JP5787301B2 (ja) | 弱塩基性薬および有機酸を含む薬物送達系 | |
| EP2265261B1 (en) | Drug delivery systems comprising weakly basic drugs and organic acids | |
| AU2007211091A1 (en) | Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids | |
| JP2022120040A (ja) | 朝の無動状態を治療するための拍動性薬物送達系 | |
| JP2008280351A5 (enExample) | ||
| JP2009537548A (ja) | ウイルス感染症の治療のための方法および組成物 | |
| JP2023009251A (ja) | アマンタジン組成物、その調製、および使用方法 | |
| CN102655866B (zh) | 糖尿病的治疗或预防药 | |
| CN107530294A (zh) | 含有质子泵抑制剂的肠溶包衣丸剂 | |
| JP2016512493A5 (enExample) | ||
| JP2008519069A5 (enExample) | ||
| US20110117070A1 (en) | Compositions and methods for treating headache | |
| JP6236079B2 (ja) | ３種の活性成分を含有する新規な時差放出医薬組成物 | |
| US10561630B2 (en) | Hydroxycitric acid compounds and capsule liquid delivery | |
| WO2017143172A1 (en) | Time release vitamins and minerals in edible oils | |
| KR102361246B1 (ko) | 시스테아민 또는 이의 염을 포함하는 서방형 약학적 조성물 | |
| US20130251793A1 (en) | Pharmaceutical composition comprising phentermine and topiramate | |
| S. Hiremath et al. | Recent patents on oral combination drug delivery and formulations | |
| AU2013204408B2 (en) | Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids | |
| US20210128496A1 (en) | Dropropizine in combination with ambroxol in the dosage form of syrup or tablets | |
| WO2017217072A1 (ja) | 生薬成分を含む肺高血圧症の予防又は治療剤 | |
| BR102016004595A2 (pt) | composição farmacêutica sólida com anti-histamínico não sedativo e descongestionante |